A Critical Review of Momordica Charantia, Curcuma longa & Gymnema sylvestre Polyherbal Systems For Diabetes Management

Diabetes mellitus represents a substantial and escalating global health burden. According to the International Diabetes Federation, over half a billion adults were affected by diabetes in 2024, and current projections suggest a sharp increase in prevalence by 2050. A considerable share of these cases remains undiagnosed or poorly controlled, leading to microvascular and macrovascular complications and imposing heavy economic and societal costs on healthcare systems, especially in low- and middle-income countries. Although several classes of antidiabetic medications are available, issues such as secondary treatment failure, adverse effects, high costs, and the requirement for lifelong therapy have maintained interest in complementary approaches, including medicinal plants and polyherbal formulations[1,2,3].

Herbal medicines have been employed for centuries in traditional systems such as Ayurveda to manage “Prameha” (diabetes), and numerous botanicals are now being evaluated for their influence on glucose homeostasis, insulin sensitivity, and diabetes?related complications. Among these, Momordica charantia L. (bitter melon), Curcuma longa L. (turmeric), and Gymnema sylvestre (gurmar) are three of the most extensively researched antidiabetic plants. M. charantia contains several bioactive constituents, including charantin, cucurbitane?type triterpenoids, flavonoids, and polysaccharides, which have been reported to enhance peripheral glucose uptake through upregulation of GLUT4, suppress hepatic gluconeogenesis, and modulate intestinal glucose absorption by affecting SGLT1 and α?glucosidase activity. Both preclinical and clinical investigations indicate that M. charantia can reduce fasting blood glucose and HbA1c levels, while also exerting favorable effects on lipid parameters and oxidative stress markers[1,3,4].

Curcuma longa exerts its antidiabetic activity mainly through polyphenolic curcuminoids, particularly curcumin, which enhance insulin sensitivity, help preserve β?cell function, and mitigate chronic inflammation and oxidative stress by modulating AMPK, PI3K/Akt, and PPARγ signaling pathways. Randomized controlled trials and mechanistic studies have shown that curcumin supplementation in individuals with type 2 diabetes or prediabetes can lower fasting glucose, HbA1c, and markers of insulin resistance. Gymnema sylvestre, which is rich in gymnemic acids and related saponins, has been reported to promote regeneration of pancreatic islet cells, stimulate insulin release, reduce intestinal glucose absorption, and inhibit α?glucosidase activity, thereby attenuating postprandial hyperglycemia. Collectively, these three botanicals act on complementary aspects of type 2 diabetes pathophysiology, namely insulin secretion and signaling, hepatic glucose production, intestinal carbohydrate digestion, and oxidative/ inflammatory stress, offering a robust scientific basis for their inclusion in a single polyherbal formulation[1,5,6].

Polyherbal formulations are gaining attention as multi?target, cost?effective therapeutic strategies that may provide synergistic effects and a more favorable safety profile compared with single?herb preparations or synthetic monotherapies. Nevertheless, their conversion into reliable dosage forms depends on rigorous standardization, careful selection of the delivery system, and thorough quality assessment. Oral capsules are especially well suited for polyherbal powders and standardized extracts, as they enhance patient compliance, protect labile phytoconstituents, and allow flexible dosing; however, they also require strict control of moisture, powder flow, content uniformity, and stability. Accordingly, this review seeks to critically evaluate the phytochemical profiles, pharmacological data, and formulation and evaluation approaches pertinent to developing polyherbal antidiabetic capsules containing Momordica charantia, Curcuma longa, and Gymnema sylvestre, with particular focus on standardization, quality control, and the translational gaps that must be resolved to support clinical adoption[1,2,7].

BOTANICAL PROFILES AND PHYTOCHEMISTRY

Momordica charantia L. (Cucurbitaceae)

Momordica charantia L. (bitter melon, karela) is a tropical vine whose fruits, leaves, and seeds are extensively employed in Ayurveda and other traditional medical systems for managing “Prameha” (diabetes) and related metabolic disorders. Its antidiabetic activity is ascribed to a complex array of secondary metabolites, notably cucurbitane?type triterpenoid glycosides and steroidal saponins[8,9].

Charantin, a mixture of sterol glucosides (β?sitosterol?β?D?glucoside and stigmasterol?β?D?glucoside), is the most widely cited marker compound for M. charantia and is frequently used to standardize extracts owing to its hypoglycaemic activity. Recent HPLC?based quantification across different genotypes has reported charantin contents of approximately 31–39 µg/g fresh weight in high?accumulating lines, highlighting clear genotype?dependent variability and supporting the feasibility of marker?based standardization. Beyond charantin, M. charantia contains numerous momordicosides, karavilosides, and related cucurbitane triterpenoids, together with flavonoids (e.g., quercetin, rutin), phenolic acids (e.g., p?coumaric acid), and polysaccharides that contribute to antioxidant, anti?inflammatory, and glucose?lowering activities. Collectively, these constituents influence key pathways involved in glucose homeostasis, including promotion of peripheral glucose uptake, inhibition of hepatic gluconeogenesis, and suppression of intestinal carbohydrate?digesting enzymes[8,9,10].

Curcuma longa L. (Zingiberaceae)

Curcuma longa L. (turmeric) is a perennial rhizomatous herb that is widely used both as a culinary spice and as a medicinal plant in Ayurveda and other traditional systems. The rhizome constitutes the principal medicinal part and is traditionally employed for inflammatory, metabolic, and hepatic conditions, including diabetes. Its phytochemical profile is dominated by non?volatile curcuminoids along with a volatile essential oil rich in turmerone?type sesquiterpenes[11]

Curcuminoids serve as the principal marker compounds for the identification and quality control of C. longa. The major curcuminoid, curcumin (diferuloylmethane), generally constitutes about 60–75% of the total curcuminoid fraction, with demethoxycurcumin and bisdemethoxycurcumin present in smaller proportions. International standards for turmeric used as a spice typically specify a minimum total curcuminoid content of approximately 2%, whereas dried rhizomes commonly contain 3–5% (w/w) total curcuminoids, varying with genotype, geographical origin, and processing conditions. Curcumin and related curcuminoids display pleiotropic biological activities, such as enhancing insulin sensitivity, preserving β?cell function, and mitigating oxidative stress and chronic inflammation through modulation of AMPK, PI3K/Akt, NF?κB, and PPARγ signaling pathways. These mechanisms help explain the reductions in fasting glucose, HbA1c, and markers of insulin resistance observed in preclinical and clinical studies of curcumin supplementation in individuals with type 2 diabetes and prediabetes[12,13]

Gymnema sylvestre (Retz.) (Apocynaceae)

Gymnema sylvestre (gurmar, “sugar destroyer”) is a woody climbing shrub indigenous to India and other tropical regions. Its leaves are traditionally employed in the management of diabetes, obesity, and dyslipidemia. The plant’s antidiabetic activity is mainly ascribed to a group of triterpenoid saponins known as gymnemic acids, together with related gymnemasaponins and other phytoconstituents.

Gymnemic acids consist of multiple analogues (commonly designated as gymnemic acids I–V and related derivatives) that share a gymnemagenin aglycone backbone with varying acyl substitutions. These compounds underlie the characteristic ability of G. sylvestre to suppress sweet taste perception and to inhibit intestinal glucose absorption. In addition to gymnemic acids, the leaves contain flavonoids, phenolic acids, anthraquinones, and other saponins that contribute to antioxidant and anti?inflammatory activities. From a pharmacological perspective, gymnemic acids have been reported to stimulate insulin secretion, promote regeneration of pancreatic islet cells, inhibit α?glucosidase activity, and reduce postprandial hyperglycemia, thereby complementing the mechanisms of M. charantia and C. longa within a polyherbal antidiabetic formulation. Recent studies have also isolated individual gymnemic acid analogues (e.g., gymnemic acid?III) using preparative HPLC, highlighting the feasibility of marker?based standardization for quality control purposes[13,14,15].

PHARMACOLOGICAL EVIDENCE:

Momordica charantia: preclinical and clinical evidence

Preclinical investigations consistently show that M. charantia extracts and isolated constituents lower blood glucose via multiple mechanisms, including promotion of peripheral glucose uptake, inhibition of hepatic gluconeogenesis, modulation of insulin signaling, and suppression of carbohydrate?digesting enzymes. In streptozotocin?induced and high?fat diet–induced diabetic models, bitter gourd preparations have been reported to improve fasting glucose levels, oral glucose tolerance, and lipid profiles, while also reducing markers of oxidative stress[9,10,16].

Clinical evidence, although heterogeneous with respect to plant part, extract type, and dosing regimen, supports a modest yet statistically significant glucose?lowering effect of M. charantia. A 2024 systematic review and meta?analysis of randomized controlled trials (RCTs) in type 2 diabetes mellitus (T2DM), assessed using the GRADE approach, reported that M. charantia supplementation significantly reduced fasting blood glucose (FBG), postprandial glucose (PPG), and HbA1c compared with placebo. Pooled data from eight RCTs (n ≈ 423) yielded weighted mean differences of approximately −0.85 mmol/L for FBG and −0.38% for HbA1c, with more consistent effects observed in trials lasting ≥12 weeks. In another recent RCT involving 50 patients with T2DM, 12 weeks of treatment with standardized bitter gourd extract capsules (1000 mg/day) significantly lowered oxidative stress (as reflected by reduced malondialdehyde levels) and increased superoxide dismutase activity, indicating antioxidant benefits in addition to glycemic improvements. Safety data across trials suggest good tolerability, with predominantly mild gastrointestinal complaints and no serious adverse events attributed to M. charantia[17,18,19,20].

Curcuma longa (curcumin): preclinical and clinical evidence

Preclinical studies indicate that curcumin and C. longa extracts enhance insulin sensitivity, protect β?cells, and mitigate inflammation and oxidative stress through modulation of AMPK, PI3K/Akt, NF?κB, and PPARγ signaling pathways. These mechanistic effects are reflected in clinically relevant improvements in both glycemic and inflammatory markers[13].

An umbrella review and updated meta?analyses published in 2023, evaluating C. longa supplementation in adults with T2DM, prediabetes, and metabolic syndrome, reported significant reductions in fasting blood glucose (mean difference ≈ −8.1 mg/dL) and HbA1c (≈ −0.13%) compared with placebo or standard care. More recent randomized controlled trials further support these observations: a 2024 study in older adults with prediabetes demonstrated that daily administration of 80 mg curcumin for 12 weeks significantly lowered HbA1c relative to placebo, indicating a potential benefit in early stages of glucose dysregulation[22].

In patients with T2DM, 12 weeks of curcumin supplementation significantly reduced FBG, HbA1c, and C?reactive protein levels, indicating concurrent antihyperglycemic and anti?inflammatory effects. Another randomized controlled trial conducted in 2025 in T2DM patients with diabetic sensorimotor polyneuropathy reported that nano?curcumin (1500 mg/day for 14 weeks) ameliorated neuropathy severity and improved several cardiometabolic risk markers, although changes in HbA1c and FBG were not statistically significant across all subgroups. Taken together, clinical evidence suggests that curcumin is most beneficial as an adjunctive therapy in early dysglycemia and in individuals with heightened inflammatory status, with a favorable safety and tolerability profile[23,24,25].

Gymnema sylvestre: preclinical and clinical evidence

Preclinical investigations demonstrate that G. sylvestre extracts and gymnemic acids enhance insulin secretion, promote β?cell regeneration, inhibit intestinal glucose absorption, and suppress α?glucosidase activity. Network pharmacology and molecular docking studies have identified AKT1, PPARG, TNF, and IL?1β as key molecular targets, with gymnemic acid I exhibiting strong binding affinity to AKT1 and stable interactions in molecular dynamics simulations, thereby supporting a multi?target antidiabetic mechanism of action[26, 27, 28].

Clinical evidence, although more limited compared with M. charantia and curcumin, is encouraging. A 2025 study combining in vitro and clinical work reported that 45 days of supplementation with G. sylvestre leaf extract (2 g/day) in human subjects significantly improved anthropometric and glycemic parameters, while cellular models showed enhanced glucose uptake and insulin secretion. Earlier trials using standardized G. sylvestre extracts (e.g., Om Santal Adivasi fraction, 1 g/day for 60 days) in patients with T2DM demonstrated reductions in fasting and postprandial blood glucose levels, along with increases in serum insulin and C?peptide, consistent with an insulinotropic effect. A 2026 mechanistic review further summarized clinical findings indicating that standardized G. sylvestre extracts improve glycemic control and modulate lipid metabolism, with additional benefits on oxidative stress and inflammation that are relevant to diabetic complications. Safety profiles are generally favorable, with mild gastrointestinal symptoms being the most frequently reported adverse effects[26,28,29].

Rationale for capsule dosage form

Oral delivery continues to be the most preferred route for antidiabetic therapy owing to its convenience, cost?effectiveness, and high patient compliance. In the case of polyherbal formulations, the selection of an appropriate dosage form must balance ease of administration, protection of labile phytoconstituents, dosing flexibility, and scalability of manufacturing. Among the available oral dosage forms, hard gelatin or HPMC capsules provide several advantages for combinations of herbal powders and standardized extracts, such as those derived from Momordica charantia, Curcuma longa, and Gymnema sylvestre[30,31,32].

Capsules allow direct filling of blended herbal powders or granulated extracts without subjecting the material to high compression forces, which is advantageous when handling hygroscopic, fibrous, or poorly compressible plant materials. This is especially relevant for M. charantia fruit powders, C. longa rhizome powders/extracts, and G. sylvestre leaf powders, which may display variable flow properties, moisture uptake, and compressibility depending on processing conditions. Encapsulation also offers superior protection against moisture, light, and oxygen compared with uncoated tablets or loose powders, thereby helping to preserve labile constituents such as curcuminoids, gymnemic acids, and cucurbitane triterpenoids[30,31,33,34].

From a patient?centric perspective, capsules are easy to swallow, effectively mask the bitter taste and strong odor associated with bitter gourd and gurmar, and permit flexible dosing through adjustment of fill weight and capsule size. Polyherbal capsules further enhance adherence by combining multiple botanicals into a single unit, thereby reducing pill burden compared with consuming individual herbal products. Regulatory and quality frameworks for herbal capsules are well established, with clear requirements for botanical identification, assay of marker compounds, microbial limits, heavy?metal testing, and stability evaluation, facilitating alignment with both AYUSH and modern pharmaceutical standards[30,35,36].

However, formulating polyherbal blends into capsules also poses several challenges, including control of moisture content, achievement of uniform fill weight, prevention of segregation among components with differing particle sizes and densities, and maintenance of chemical stability of key marker compounds throughout the product’s shelf life. These issues can be addressed through appropriate drying and sieving steps, incorporation of glidants and lubricants (e.g., colloidal silicon dioxide, magnesium stearate), and selection of moisture?resistant capsule shells such as HPMC. Overall, capsules constitute a scientifically and pharmaceutically sound dosage form for a standardized polyherbal antidiabetic product combining M. charantia, C. longa, and G. sylvestre, provided that formulation design and quality control measures are rigorously applied[30,32,34].

Formulation design considerations for polyherbal capsules

Developing a robust polyherbal capsule containing Momordica charantia, Curcuma longa, and Gymnema sylvestre demands careful control of raw material quality, selection of extracts and powders, choice of excipients, and implementation of marker?based standardization. Herbal powders and extracts frequently exhibit hygroscopicity, poor flow properties, and batch?to?batch variability in phytochemical composition, which can compromise capsule fill uniformity, stability, and therapeutic consistency. A rational formulation strategy therefore integrates standardized extracts (targeting key marker compounds) with processed powders and appropriate excipients to achieve satisfactory flow characteristics, moisture control, and dosing precision, supported by validated analytical methods for charantin, curcuminoids, and gymnemic acids[33,37].

Table 1. Extract versus powder: implications for polyherbal antidiabetic capsules [35,37,38]

Table 2. Common challenges in polyherbal capsule formulation and practical solutions[38,39,40]

Evaluation parameters:

Quality evaluation of polyherbal antidiabetic capsules containing Momordica charantia, Curcuma longa, and Gymnema sylvestre should adopt an integrated framework consistent with WHO guidelines for herbal medicines, the Indian Pharmacopoeia (IP), and the Ayurvedic Pharmacopoeia of India (API). This encompasses pre?formulation characterization of raw materials, in?process controls during blending and capsule filling, and comprehensive testing of the finished product for identity, purity, potency, and stability. Critical tests include physicochemical parameters (weight variation, content uniformity, disintegration, dissolution), safety?related limits (microbial contamination, heavy metals, pesticide residues), and marker?based assays using validated HPLC/HPTLC methods for charantin, curcuminoids, and gymnemic acids. Stability studies conducted under accelerated and long?term conditions, designed in accordance with ICH Q1A principles, ensure that critical quality attributes and marker contents remain within specified limits throughout the product’s shelf life[41,42,43].

Table 3: Quality control testing framework for polyherbal antidiabetic capsules[44-47]